Corpus ID: 36730425

In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis.

  title={In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis.},
  author={J. Barr and E. Smyth and G. Hogg},
  journal={European journal of clinical microbiology \& infectious diseases : official publication of the European Society of Clinical Microbiology},
  volume={9 11},
  • J. Barr, E. Smyth, G. Hogg
  • Published 1990
  • Medicine
  • European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
The interaction between imipenem and two glycopeptides against staphylococci was examined for potential synergy. Imipenem in combination with vancomycin or teicoplanin exerted a synergistic or additive effect against a majority of Staphylococcus aureus and Staphylococcus epidermidis isolates tested by the checkerboard method. Synergistic inhibitory effects were frequently accompanied by synergistic bactericidal effects. For a proportion of bacterial isolates of both species, the demonstration… Expand
In vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative Staphylococcus.
Increasing the cefpirome concentration to 0.5 or 1 times the MIC combined with vancomycin at the same concentration improved the bacterial killing rate and a bactericidal effect was obtained in 9 or 24 h instead of in 24 or 48 h, respectively. Expand
In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus.
The bactericidal activity in vitro of cefpirome plus either vancomycin or teicoplanin was compared with that of a cefamandole-vancomycin combination against ten clinical isolates of homogeneousExpand
Combination Effect of Vancomycin and β-Lactams against a Staphylococcusaureus Strain, Mu3, with Heterogeneous Resistance to Vancomycin
This study implicated the unpredictable nature of combination therapy of β-lactams and vancomycin against S. aureus with reduced susceptibility to vancomYcin in clinical strain Mu3, which displays heterogeneous resistance to van comycin. Expand
In Vitro Synergistic Effects of Double and Triple Combinations of β-Lactams, Vancomycin, and Netilmicin against Methicillin-Resistant Staphylococcus aureusStrains
The aim of this study was to exhaustively compare the effects of different combinations of a β-lactam, vancomycin, and/or an aminoglycoside against 32 clinical MRSA strains with different aminglycoside susceptibility patterns. Expand
Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin
It is concluded that the combination of vancomycin and β-lactams with antistaphylococcal activity is an effective regimen for the treatment of infections with clinical strains of stAPHylococci which demonstrate reduced susceptibility to glycopeptides. Expand
In Vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus
This study demonstrates the antibacterial activity of PAAG against clinical isolates of methicillin and mupirocin-resistant Staphylococcus aureus and indicates that this class of bacterial permeabilizing glycopolymers may provide a new tool in the battle against multidrug-resistant bacteria. Expand
β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA
The combination of vancomycin and beta-lactams significantly improved antibacterial activity against VSSA, hVISA, and VISA strains compared to the activity of any agent alone, supporting the potential use of van comycin–beta- lactam combination therapy in infections caused by MRSA. Expand
In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections
In vitro evidence of synergy between glycopeptides, fluoroquinolones (levofloxacin) and β-lactams and of reduction of mutational frequencies by combinations are suggestive for a potential role in empirical therapy of severe pneumonia with suspected MRSA etiology. Expand
Synergistic Activity of Ceftobiprole and Vancomycin in a Rat Model of Infective Endocarditis Caused by Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus
Ceftobiprole was efficacious both as monotherapy and in combination with vancomycin in treating MRSA and GISA infections in a rat infective endocarditis model and warrants further evaluation. Expand
Glycopeptide Resistance in Coagulase-Negative Staphylococci
In studies of glycopeptide-resistant staphylococci, resistance to teicoplanin was generally easier to obtain than resistance to vancomycin, and the levels of teicountin resistance were higher. Expand